Over 150,000 Mobi-C Discs have been implanted in 25 countries since 2004. 

Mobi-C Cervical Disc was the first cervical disc in the United States approved to treat more than one level of the cervical spine. Mobi-C was determined by the FDA to be statistically superior to fusion at 7 years  for two-level cervical disc replacement, based on the primary study endpoint of a prospective, concurrently controlled and randomized, multi-center clinical trial.1  At 10 years, all patient-reported outcomes were equivalent to or improved from 7 years.3.4

   

   

Mobile Bearing

  • Controlled Mobility: Restoring natural motion to the cervical spine - The controlled mobility of the patented mobile core is the foundation of Mobi-C. With vertebrae and neck muscle movement, the Mobi-C implant is free to twist and slide left-to-right, and front-to-back, as well as rotate. 

Bone Sparing

  • Bone Chiseling: Preserves Bone Surface. Mobi-C's mobile core is designed to create low stress at the implant to bone interface. Implantation of the Mobi-C requires no invasive keels or screws, no bone removal for keel preparation, and no additional operative steps for keel cutting. 

Ease of Insertion

  • One-Step Insertion: To insert the Mobi-C Cervical Disc, no additional exposure or operative steps are required for screw or keel placement, eliminating the need for drilling or chiseling.
Mobi-C Self-Adjusting

Self-Adjusting - A return to physiological mobility

The center of rotation at each level of the cervical spine is variable and constantly changing.5 Mobi-C was designed to adapt to the Instantaneous Axis of Rotation through its self-adjusting mobile core. The mobile core allows the vertebrae above and below the disc to move, to maintain normal neck motion. 

Proven Clinical Success

Mobi-C was approved via an Investigational Device Exemption (IDE) clinical trial involving 599 patients comparing Mobi-C to Anterior Cervical Discectomy and Fusion (ACDF) at one and two contiguous levels.
Mobi-C is the first cervical disc FDA approved for both one and two-level indications. The U.S. Food and Drug Administration (FDA) approved an update to the Mobi-C labeling to include seven-year clinical results.

Resources

Explore Medical Educational Opportunities

Product-Specific Surgeon Certification

Mobi-C® User Certification Program

Mobi-C Education

Important Information

Additional Information